Treatment of Actinic Keratosis With 5% KOH Solution

Inclusion Criteria: * Written informed consent * Age: 30 to 80 years * Adults with AK grade I (mild) or II (moderate) Exclusion Criteria: * Number of lesions requiring treatment \> 10 * Lesion to be treated \> 20 mm (maximum diameter) * Lesions directly adjoining to the eyes, eyelids, nostrils, mouth or mucosal tissue, * Need for topical treatment of a cancerous area * Presence of a relapsing, persistent, indurated, thickened, painful, bleeding, ulcerated and/or rapidly growing lesion * Presence of a persistent or relapsing lesion despite appropriate treatment with AKOHDerm or another appropriate treatment * High risk of progression of AK according as assessed by a medical doctor * Pharmacological or physical local therapy of AK in the area foreseen for treatment dur-ing the last 12 weeks * Treatment with systemic corticosteroids during the last 2 weeks * Planned concomitant treatment of the same AK lesions during the study in addition to study treatment * Other skin diseases in the area of application which might interfere with clinical signs * Known predisposition for hypertrophic scarring / keloidosis * Primary or secondary immunodeficiency * Treatment with interferons, interferon inducers or immunomodulators during the last 4 weeks * Pregnancy and lactation * No reliable contraception in women of child-bearing potential * Other serious diseases which are according to the investigator in conflict with the par-ticipation * Obvious unreliability or lack of cooperation - known addiction to alcohol, medicinal products or drugs * Dependent relationship with sponsor or investigator * Participation in a clinical trial within the last 30 days * Previous participation in this study